The CD133 aptamer used in this study has been demonstrated to target the AC133 epitope [4], leading to an increased concentration of DOX in the liver cancer stem cells via the CD133 aptamer-mediated delivery of DOX, compared with that of free DOX (Figure 3 and Figure 6). This evidence concerns the gene PROM1 and liver cancer.